Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11999731
EGFR dimer disruptors and use of the same
granted -
US 11999693
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
granted -
US 11998521
Use of an RXR agonist in treating drug resistant HER2+ cancers
granted -
US 11999683
Lipocationic dendrimers and uses thereof
granted -
US 11992495
Enhancing GABA's ability to modulate immune responses
granted -
US 11993573
Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents
granted -
US 11993638
GM-CSF mimetics and methods of making and using same
granted -
US 11992532
Hydrogels and methods of using the same
granted -
US 11993789
Pichinde virus reverse genetics systems and methods of use
granted -
US 11987600
Contraceptive use of triterpenoids
granted -
US 11986561
Wound dressings and applications thereof
granted -
US 11986442
Inhibition of respiratory complex III by ligands that interact with a regulatory switch
granted -
US 11986533
Macromonomers and bottle brush polymers for delivery of biological agents
granted -
US 11986515
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)
granted -
US 11981662
Pyrazole derivatives with anticancer activity
granted -
US 11980645
Bile acids and use in disease treatment
granted -
US 11980634
Method of reconstituting liposomal annamycin
granted -
US 11981700
Pyrrolopyrimidine nucleosides and analogs thereof
granted -
US 11981760
Therapeutic hydrogels and contact lens for corneal melting
granted -
US 11981740
BAFF-R antibodies and uses thereof
granted -
US 11981571
Identification and optimization of carbon radicals on hydrated graphene oxide for ubiquitous antibacterial coatings
granted -
US 11981736
Antibodies specific to glycosylated PD-1 and methods of use thereof
granted -
US 11974992
Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
granted -
US 11975035
Methods for treating microbial infections using caudovirales bacteriophages
granted -
US 11975022
Trace element compositions, methods of making and use
granted -
US 11976293
Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
granted -
US 11974730
Minimally-invasive measurement of esophageal inflammation
granted -
US 11974988
Neuroprotective compositions and methods of using the same
granted -
US 11976128
Human PD-L2 antibodies and methods of use therefor
granted -
US 11976274
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
granted -
US 11976309
Fusion proteins and methods for site-directed genome editing
granted -
US 11969401
Compositions and methods for treating or limiting development of age-related macular degeneration
granted -
US 11969522
Use of immune modulators to improve nerve regeneration
granted -
US 11969511
Methods and compositions for antimicrobial treatment
granted -
US 11970711
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11971410
Methods of classifying response to immunotherapy for cancer
granted -
US 11969499
Hydrogel delivery of sting immunotherapy for treatment cancer
granted -
US 11970534
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
granted -
US 11969501
Auris formulations for treating otic diseases and conditions
granted -
US 11970521
Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
granted -
US 11969470
Topiramate compositions and methods of making and using the same
granted -
US 11965190
Vectors, genetically modified bacteria, and methods of making and using
granted -
US 11963533
Compositions and methods for treating Liberibacter diseases and other bacterial diseases
granted -
US 11964985
Anti-cancer compounds targeting Ral GTPases and methods of using the same
granted -
US 11965159
Compositions and methods for regulating proteins and nucleic acids activities
granted -
US 11963945
Ozonides for treating or preventing virus infections
granted -
US 11958901
Anti-CXCR5 antibodies and compositions and uses thereof
granted -
US 11958849
GLS1 inhibitors for treating disease
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory